Featured Research

from universities, journals, and other organizations

Multivisceral Transplant Survival Rates Improve With New Treatment, Study Finds

Date:
October 6, 2009
Source:
University of Pittsburgh Schools of the Health Sciences
Summary:
Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management, according to new study. Some of these patients are the longest surviving intestinal and multivisceral transplant recipients in the world, surviving more than 19 years post-transplant with excellent quality of life.

Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management, said researchers at the Thomas E. Starzl Transplantation Institute in a study published in the October issue of Annals of Surgery.

Related Articles


Led by Kareem Abu-Elmagd, M.D., Ph.D., director, Intestinal Rehabilitation and Transplantation Center, Thomas E. Starzl Transplantation Institute, and professor of surgery, University of Pittsburgh School of Medicine, researchers assessed the evolution of intestinal and multivisceral transplantation by reporting the first 500 such transplants conducted at the University of Pittsburgh Medical Center (UPMC) from 1990 to 2008, which represent more than 25 percent of the worldwide experience.

"The findings support the minimization of immunosuppressive therapy for intestinal and multivisceral transplant patients," said Dr. Abu-Elmagd. "Our research found that survival rates for such transplant recipients greatly increased as treatment strategies evolved; this included the reduction in the use of immunosuppressive therapy."

Over nearly two decades divided into three eras, 453 patients received 215 intestine, 151 liver-intestine and 134 multivisceral transplants. Some of these patients are the longest surviving intestinal and multivisceral transplant recipients in the world, surviving more than 19 years post-transplant with excellent quality of life.

During what the researchers dubbed Era I (1990 to 1994), transplant recipients were treated with the immunosuppressive drug tacrolimus and steroids. In 1994, this protocol was discontinued due to high mortality and morbidity rates. The five-year survival rate for these patients was 40 percent.

Era II (1995 to 2001) introduced the use of donor bone marrow to encourage organ acceptance. The five-year survival rate for these patients was 56 percent.

During Era III (2001 to 2008), patients were given a pre-conditioning protocol with agents that deplete recipients' own immune calls. Their post-transplant drug regimen was minimal and was initiated with tacrolimus, followed by steroids when necessary. Tacrolimus doses were subsequently spaced to a single dose twice to three times per week with a careful weaning process that started three to six months after transplant. Through the use of new immunosuppressive and management strategies, the five-year survival rate for these patients increased to 68 percent, which is similar to any other abdominal and thoracic organ transplant procedure.

"We have learned that patients who are using multiple anti-rejection drugs over a period of several years may experience long-term detrimental effects, which erodes survival rates beyond 10 years post-transplant," noted Dr. Abu-Elmagd. "With that in mind, we will strive to reduce use of these drugs as much as possible in our patients."

Study co-authors are Guilherme Costa, M.D., Geoffrey J. Bond, M.D., Kyle Soltys, M.D., Rakesh Sindhi, M.D., Tong Wu, M.D., Darlene A. Koritsky, R.N., Bonita Schuster, R.N., Lillian Martin, A.R.T., Ruy J. Cruz, M.D., Noriko Murase, M.D., Adriana Zeevi, M.D., Maher O. Ayyash, M.D., Laura Matarese, Ph.D., Abhinav Humar, M.D., and George Mazariegos, M.D., UPMC Thomas E. Starzl Transplantation Institute, Pittsburgh; and William Irish, Ph.D., CTI, Clinical Trials and Consulting Services, Cincinnati.


Story Source:

The above story is based on materials provided by University of Pittsburgh Schools of the Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Schools of the Health Sciences. "Multivisceral Transplant Survival Rates Improve With New Treatment, Study Finds." ScienceDaily. ScienceDaily, 6 October 2009. <www.sciencedaily.com/releases/2009/10/091005111647.htm>.
University of Pittsburgh Schools of the Health Sciences. (2009, October 6). Multivisceral Transplant Survival Rates Improve With New Treatment, Study Finds. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2009/10/091005111647.htm
University of Pittsburgh Schools of the Health Sciences. "Multivisceral Transplant Survival Rates Improve With New Treatment, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2009/10/091005111647.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins